Yangtze River Pharmaceutical Group Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Shandong Danhong Pharmaceutical Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Humanwell Healthcare (group) Co., Ltd.

Medshine Discovery Inc.

Discovery Energy, LLC

Qilu Pharmaceutical Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Genfleet Therapeutics (shanghai) Inc.

Luoxin Pharmaceutical (shanghai) Co., Ltd.

Genfleet Therapeutics Inc.

Weidong Li

Zheng Wang

Haiying He

Charles Z Ding

Xiaolin Li

Shuhui Chen

Yuan Chen

Zhi Luo

Songliang Wu

Yuhe Wang

Dakun Qin

Hongwei Li

Lihong Hu

Feng Xu

Zhigan Jiang

Weihua Shi

Linghui Wu

Minggao Zeng

Kunmin Lai

Yong Wang

Cong Wang

Hui Liu

Yong Xu

Lie Li

Jianyu Lu

Lu Huang

Cailin Wang

Xuehai Wang

Ronghua Tu

Huijun He

Shenyi Shi

Jie Shen

Hailiang Chen

Wenjie Sun

Yang YuE

Jimeng Wang

Biao Deng

Jian Li

Peng Zhang

Peng Li

Cheng Li

Xiquan Zhang

Tie-Lin Wang

Lingyun Wu

Mark J Huibregtse

Rui Zhao

Lifang Wu

Zhigang Huang

Zhaobing Xu

Vaibhav Prabhakar Wagh

Jiaqiang Dong

Zongbin Li

Yingchun Liu

Hualing Xiao

Bingjie Ren

Jinhong Li

Zhijuan Chen

Vania Galvan

Haiting Wang

Jacky Zhang

Engine

Provided are a crystal form of a tricyclic compound and a preparation process thereof. Also provided is an application of the crystal form in preparing a drug for treating a disease related to a sphingosine-1-phosphate subtype 1 (S1P1) receptor. 

Crystal and salt forms of tricyclic compound and preparation process thereof

Disclosed in the present invention are a crystal form and salt form of a TGF-&#x3b2;R1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers. 

Crystal form and salt form of TGF-&#x3b2;RI inhibitor and preparation method therefor

Disclosed in the present disclosure are a crystal form of a &#x3b2;-lactamase inhibitor and a preparation method therefor, as well as an application of the crystal form in preparing a &#x3b2;-lactamase inhibitor drug. (I) 

Crystal form of &#x3b2;-lactamase inhibitor and preparation method therefor

Disclosed are a crystalline or amorphous form of steroid derivative FXR agonist (formula I), and a preparation method therefor, and a crystalline composition and pharmaceutical composition comprising the crystalline or amorphous form, and the use of same in the preparation of a drug for treating or preventing various conditions associated with FXR. 

Crystalline or amorphous form of steroid derivative FXR agonist, preparation method therefor and use thereof

Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer. 

Crystal form of estrogen receptor inhibitor and preparation method therefor

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound has the structure of Compound 2. 

Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

Disclosed are a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Crystal form of orexin receptor antagonist compound, and preparation method and application thereof

Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof. 

Process for preparing 1-isobutyryl-1'-((1-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-benzo[D]imidazol-2-yl)methyl)spiro[azetidine-3,3&#x2032;-indolin]-2&#x2032;-one

Disclosed are a preparation method of an orexin receptor antagonist compound 5-3, Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of the preparing the orexin receptor antagonist compound 5-3 and its crystalline forms, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Crystal form B of 1-isobutyryl-1'-((1-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-2-yl)methyl)spiro[azetidine-3,3&#x2032;-indolin]-2&#x2032;-one

A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like. 

Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1,5-alpha]benzimidazole compound and a preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound is represented by formula I: 

Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

Growing community of inventors

Shanghai, China

Weidong Li